Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients
Study Details
Study Description
Brief Summary
The purpose of this study is to determine whether eradication of Helicobacter pylori infection is effective in the improvement of platelet counts in children and adolescents with chronic ITP.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
Helicobacter pylori infection has been associated with Immune Thrombocytopenic Purpura (ITP), and there is scientific evidence for the investigation and treatment of this bacterium for adult patients with ITP. However, in children this causal association is not clear, with few published studies.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
No Intervention: H. pylori no treatment Observational group, with clinical and platelet count follow-up |
|
Experimental: H. pylori triple therapy Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days. |
Drug: H. pylori triple therapy
Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- platelet response [1 year]
Responders: Complete Response (CR), persistent elevation of platelet count to >150×109/L; Partial Response (PR), elevation between 20 and 30×109/L above the baseline values, but between 50 and 149×109/L; No Responders: any of the above categories.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
clinical diagnosis of chronic immune thrombocytopenic purpura
-
children and adolescents up to 20 years
Exclusion Criteria:
-
known hypersensitivity to any of the drugs
-
recent treatment for H. pylori eradication
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Irmandade da Santa Casa de Misericordia se Sao Paulo | Sao Paulo | Brazil | 01221-020 | |
2 | Centro de Hematologia de Sao Paulo | Sao Paulo | Brazil | 01401-000 | |
3 | Federal University of Sao Paulo | Sao Paulo | Brazil | 04021-001 | |
4 | Hospital Estadual Infantil Darcy Vargas | Sao Paulo | Brazil | 05614-040 |
Sponsors and Collaborators
- Federal University of São Paulo
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Investigators
- Principal Investigator: Elisabete Kawakami, Professor, Federal University of Sao Paulo
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 08/56706-0